Cargando…

Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling

BACKGROUND: Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yu, Li, Li, Lu, Zongshi, Hu, Yingru, Zhang, Hexuan, Sun, Fang, Li, Qiang, He, Chengkang, Shu, Wentao, Wang, Lijuan, Cao, Tingbing, Luo, Zhidan, Yan, Zhencheng, Liu, Daoyan, Gao, Peng, Zhu, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375510/
https://www.ncbi.nlm.nih.gov/pubmed/35904193
http://dx.doi.org/10.1161/JAHA.121.025328
_version_ 1784767980014403584
author Zhao, Yu
Li, Li
Lu, Zongshi
Hu, Yingru
Zhang, Hexuan
Sun, Fang
Li, Qiang
He, Chengkang
Shu, Wentao
Wang, Lijuan
Cao, Tingbing
Luo, Zhidan
Yan, Zhencheng
Liu, Daoyan
Gao, Peng
Zhu, Zhiming
author_facet Zhao, Yu
Li, Li
Lu, Zongshi
Hu, Yingru
Zhang, Hexuan
Sun, Fang
Li, Qiang
He, Chengkang
Shu, Wentao
Wang, Lijuan
Cao, Tingbing
Luo, Zhidan
Yan, Zhencheng
Liu, Daoyan
Gao, Peng
Zhu, Zhiming
author_sort Zhao, Yu
collection PubMed
description BACKGROUND: Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and without diabetes. However, the underlying mechanism remains elusive. METHODS AND RESULTS: Dahl salt‐sensitive rats and salt‐insensitive controls were fed with 8% high‐salt diet and some of them were treated with canagliflozin. The blood pressure, urinary sodium excretion, and vascular function were detected. Transient receptor potential channel 3 (TRPC3) knockout mice were used to explain the mechanism. Canagliflozin treatment significantly reduced high‐salt‐induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt‐sensitive hypertensive rats. Assay of vascular function and proteomics showed that canagliflozin significantly inhibited vascular cytoplasmic calcium increase and vasoconstriction in response to high‐salt diet. High salt intake increased vascular expression of TRPC3 in salt‐sensitive rats, which could be alleviated by canagliflozin treatment. Overexpression of TRPC3 mimicked salt‐induced vascular cytosolic calcium increase in vitro and knockout of TRPC3 erased the antihypertensive effect of canagliflozin. Mechanistically, high‐salt‐induced activation of NCX1 (sodium‐calcium exchanger 1) reverse mode increased cytoplasmic calcium level and vasoconstriction, which required TRPC3, and this process could be blocked by canagliflozin. CONCLUSIONS: We define a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high‐salt‐induced hypertension, which can be improved by canagliflozin treatment. This pathway is potentially a novel therapeutic target to antagonize salt‐sensitive hypertension.
format Online
Article
Text
id pubmed-9375510
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93755102022-08-17 Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling Zhao, Yu Li, Li Lu, Zongshi Hu, Yingru Zhang, Hexuan Sun, Fang Li, Qiang He, Chengkang Shu, Wentao Wang, Lijuan Cao, Tingbing Luo, Zhidan Yan, Zhencheng Liu, Daoyan Gao, Peng Zhu, Zhiming J Am Heart Assoc Original Research BACKGROUND: Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and without diabetes. However, the underlying mechanism remains elusive. METHODS AND RESULTS: Dahl salt‐sensitive rats and salt‐insensitive controls were fed with 8% high‐salt diet and some of them were treated with canagliflozin. The blood pressure, urinary sodium excretion, and vascular function were detected. Transient receptor potential channel 3 (TRPC3) knockout mice were used to explain the mechanism. Canagliflozin treatment significantly reduced high‐salt‐induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt‐sensitive hypertensive rats. Assay of vascular function and proteomics showed that canagliflozin significantly inhibited vascular cytoplasmic calcium increase and vasoconstriction in response to high‐salt diet. High salt intake increased vascular expression of TRPC3 in salt‐sensitive rats, which could be alleviated by canagliflozin treatment. Overexpression of TRPC3 mimicked salt‐induced vascular cytosolic calcium increase in vitro and knockout of TRPC3 erased the antihypertensive effect of canagliflozin. Mechanistically, high‐salt‐induced activation of NCX1 (sodium‐calcium exchanger 1) reverse mode increased cytoplasmic calcium level and vasoconstriction, which required TRPC3, and this process could be blocked by canagliflozin. CONCLUSIONS: We define a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high‐salt‐induced hypertension, which can be improved by canagliflozin treatment. This pathway is potentially a novel therapeutic target to antagonize salt‐sensitive hypertension. John Wiley and Sons Inc. 2022-07-29 /pmc/articles/PMC9375510/ /pubmed/35904193 http://dx.doi.org/10.1161/JAHA.121.025328 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Zhao, Yu
Li, Li
Lu, Zongshi
Hu, Yingru
Zhang, Hexuan
Sun, Fang
Li, Qiang
He, Chengkang
Shu, Wentao
Wang, Lijuan
Cao, Tingbing
Luo, Zhidan
Yan, Zhencheng
Liu, Daoyan
Gao, Peng
Zhu, Zhiming
Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title_full Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title_fullStr Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title_full_unstemmed Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title_short Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
title_sort sodium‐glucose cotransporter 2 inhibitor canagliflozin antagonizes salt‐sensitive hypertension through modifying transient receptor potential channels 3 mediated vascular calcium handling
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375510/
https://www.ncbi.nlm.nih.gov/pubmed/35904193
http://dx.doi.org/10.1161/JAHA.121.025328
work_keys_str_mv AT zhaoyu sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT lili sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT luzongshi sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT huyingru sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT zhanghexuan sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT sunfang sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT liqiang sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT hechengkang sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT shuwentao sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT wanglijuan sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT caotingbing sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT luozhidan sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT yanzhencheng sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT liudaoyan sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT gaopeng sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling
AT zhuzhiming sodiumglucosecotransporter2inhibitorcanagliflozinantagonizessaltsensitivehypertensionthroughmodifyingtransientreceptorpotentialchannels3mediatedvascularcalciumhandling